Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Mark Cook et al.|New England Journal of Medicine|2023Cited by 695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsSergio Giralt, Steven M. Devine, Luciano J. Costa et al.|Biology of Blood and Marrow Transplantation|2013Cited by 402